Medical Innovation Exchange

Merck & Co. ditches oncolytic virus Cavatak 4 years after buying Viralytics

https://www.fiercebiotech.com/biotech/merck-ditches-cavatak-more-four-years-after-buying-viralytics

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!